Lärkberget Investor Relations Material
Latest events
Investor Update
Lärkberget
Q4 2024
14 Feb, 2025
Investor Update
28 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Lärkberget AB
Access all reports
CombiGene AB is a biotechnology company based in Sweden, focusing on developing gene therapies for severe neurological and psychiatric disorders. The company's primary projects include treatments for drug-resistant focal epilepsy and severe chronic pain. CombiGene utilizes gene therapy vectors, specifically adeno-associated virus (AAV) vectors, to deliver therapeutic genes. The company operates in collaboration with external research entities and contract research organizations to develop its therapeutic candidates from preclinical stages to proof of concept, aiming for subsequent commercialization through strategic partnerships. The company is headquartered in Lidingö, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
LARK
Country
🇸🇪 Sweden